0.00Open0.00Pre Close0 Volume0 Open Interest7.00Strike Price0.00Turnover0.00%IV-204.35%PremiumAug 16, 2024Expiry Date4.70Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.52Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Verastem Stock Discussion
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed ...
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 ...
Verastem Oncology, a biopharmaceutical company listed on Nasdaq under the ticker VSTM, has recently announced the commencement of dosing for the first patient in a Phase 1/2 clinical trial in China. This trial, conducted by GenFleet Therapeutics, aims to evaluate GFH375/VS-7375, a novel KRAS G12D (ON/OFF) inhibitor. $Verastem (VSTM.US)$